Savara Inc Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
Savara Inc (SVRA) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $0 as of 2013-09-30, per its 10-Q filed 2013-11-04.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2014-03-26
- 2013-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $0.00.
- 2013-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $0.00.
- 2013-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value -$170.00K.
- 2012-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $142.50K; Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value as first filed -$142.50K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value as first filed |
|---|---|---|
| 2013-09-30 | $0.00 10-Q · filed 2013-11-04 | |
| 2013-06-30 | $0.00 10-Q · filed 2013-08-05 | |
| 2013-03-31 | -$170.00K 10-Q · filed 2013-05-15 | |
| 2012-12-31 | $142.50K 10-K · filed 2014-03-26 | -$142.50K 10-K · filed 2013-03-19 |
| 2012-09-30 | -$176.40K 10-Q · filed 2012-11-05 | |
| 2012-06-30 | -$121.13K 10-Q · filed 2012-08-06 | |
| 2011-12-31 | -$140.13K 10-K · filed 2013-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |